Umbralisib: all 28 studies that test it

Page 1 of 1. Open to participants first (0), then studies with results posted, then the rest; newest registration first within each.

• Acalabrutinib, Umbralisib, and Ublituximab for the Treatment of Previously Untreated Mantle Cell LymphomaActive, not recruitingNCT04783415Phase 2Results posted
• Clinical Trial of Ublituximab and Umbralisib With CHOP (U2-CHOP) Followed by U2 Maintenance (U2-CHOP-U2) in Previously Untreated Mantle Cell Lymphoma (MCL)TerminatedNCT04692155Phase 1/2Results posted
• Acalabrutinib, Umbralisib, and Ublituximab (AU2) In Relapsed and Untreated CLLActive, not recruitingNCT04624633Phase 2Results posted
• Ublituximab Followed by Response-driven Addition of Umbralisib for Treatment-naive Follicular or Marginal Zone LymphomaCompletedNCT04508647Phase 2Results posted
• TGR-1202 (Umbralisib) in Treatment Naïve Patients With Chronic Lymphocytic Leukemia (CLL)TerminatedNCT04163718Phase 2Results posted
• Umbralisib Plus Ublituximab (U2) in Progressive CLL After Novel TherapyTerminatedNCT04149821Phase 2Results posted
• Umbralisib and Rituximab as Initial Therapy for Patients With Follicular Lymphoma and Marginal Zone LymphomaTerminatedNCT03919175Phase 2Results posted
• Study to Assess Umbralisib Plus Ublituximab in Participants With Treatment Naïve Follicular LymphomaTerminatedNCT03828448Phase 2Results posted
• Umbralisib and Pembrolizumab in Treating Patients With Relapsed or Refractory Classical Hodgkin LymphomaTerminatedNCT03776864Phase 2Results posted
• Study to Assess the Efficacy and Safety of Umbralisib in Participants With Non-Follicular Indolent Non-Hodgkin's LymphomaCompletedNCT03364231Phase 2Results posted
• TGR1202 in Relapsed and Refractory Follicular LymphomaTerminatedNCT03178201Phase 2Results posted
• TGR-1202 and Ibrutinib in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell LymphomaCompletedNCT02874404Phase 2Results posted
• Carfilzomib and TGR-1202 in Treatment of R/R LymphomaTerminatedNCT02867618Phase 1/2Results posted
• Evaluate the Efficacy and Safety of TGR-1202 in Participants With Chronic Lymphocytic Leukemia Who Are Intolerant to Prior TherapyTerminatedNCT02742090Phase 2Results posted
• A Study to Evaluate the Safety and Efficacy of Ublituximab in Combination With Umbralisib for Participants Previously Enrolled in Protocol UTX-TGR-304TerminatedNCT02656303Phase 2Results posted
• Ublituximab + TGR-1202 Compared to Obinutuzumab + Chlorambucil in Participants With Untreated and Previously Treated Chronic Lymphocytic LeukemiaTerminatedNCT02612311Phase 3Results posted
• A Phase I/Ib Safety and Efficacy Study of the PI3K-delta Inhibitor TGR-1202 and Ibrutinib in Patients With CLL or MCLCompletedNCT02268851Phase 1Results posted
• Tazemetostat in Combination With Umbralisib and Ublituximab for the Treatment Relapsed or Refractory Follicular LymphomaWithdrawnNCT05152459Phase 1/2
• Lenalidomide, Umbralisib, and Ublituximab for the Treatment of Relapsed or Refractory Indolent Non-Hodgkin Lymphoma or Mantle Cell LymphomaWithdrawnNCT04635683Phase 1
• Combination of Pembrolizumab With TGR-1202 in Patients With Relapsed/Refractory CLL and B-cell NHLActive, not recruitingNCT03283137Phase 1
• Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular LymphomaActive, not recruitingNCT03269669Phase 2
• Extension Trial of Ublituximab and TGR-1202 in Combination or as Single Agents in Subjects Currently Receiving Treatment on Ublituximab and/or TGR-1202 TrialsTerminatedNCT03207256Phase 2
• Study of Immunotherapy in Combination With Ublituximab and Umbralisib in Patients With Relapsed-refractory CLL or Richter's TransformationCompletedNCT02535286Phase 1
• TGR-1202 + Ruxolitinib PMF PPV-MF PET-MF MDS/MPN Polycythemia Vera Resistant to HydroxyureaCompletedNCT02493530Phase 1
• Novel PI3K Delta Inhibitor TGR-1202, in Combination With Brentuximab Vedotin for Hodgkin's Lymphoma PatientsCompletedNCT02164006Phase 1
• TGR-1202, a PI3K Delta Inhibitor, in Combination With Obinutuzumab and Chlorambucil in Patients With Chronic Lymphocytic Leukemia (CLL)CompletedNCT02100852Phase 1
• Ublituximab in Combination With TGR-1202 +/- Ibrutinib or Bendamustine in Patients With B-cell MalignanciesCompletedNCT02006485Phase 1
• Evaluate the Safety and Efficacy of TGR 1202 in Patients With Relapsed or Refractory Hematologic MalignanciesCompletedNCT01767766Phase 1

← Umbralisib overview